AIM Breakfasts

AIM BREAKFAST – 7th September 2016

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 1,005

Total number of AIM Companies trading: 990*
* As at 05 September 2016

Dish of the Day:

Innovaderma*, (IDP.L) the hair-loss treatment, haircare and skincare company joins the Main Market today

Off the Menu:

Sweett Group (CSG.L) leaving aim after unconditional offer for the company

Set Menu ISDX Growth:

Total number of ISDX Growth Market Companies (Incl Susp): *

Total number of ISDX Growth Market Companies trading: *
* As at 05 September 2016

Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?

Jackpotjoy—Press reports Canadian online Bingo firm currently known as Intertain (TSX) to vote on an October IPO in London

Misys— The press reports that the Banking Technology provider owned by Vista Equity Partners is seeking a £5.5bn float in London

Bacanora Lithium— To list on AIM around 28 Sep as holding company for TSX listed Bacanora Minerals at £100m market cap

Aura Energy—ASX listed uranium developer (ASX:AEE) expected to join AIM 8 September raising up to £2.85m at £8.1m mkt cap


Breakfast Buffet

Petards Group* (PEG.L) 17.75p £6.2m

Interims from the developer of advanced security and surveillance systems. Fifth consecutive half of profit growth. Total revenues increased 22% to £7.4m, with total  EBITDA up 29% to £786k and diluted EPS up 25% to 0.95p.

The £12m period end order book has been further boosted by the receipt of over £4m of orders primarily for Petards eyeTrain systems for commuter trains. 10.9x diluted 2016E earnings falling to 9.6x for 2017.


Marlowe PLC (MRL.L) 167.5p £35.8m

Marlowe, formed to acquire and develop target businesses operating in the outsourced business services sector in the UK  has released an AGM Statement. Trading in line. Integration going to plan. Continues to seek opportunities to add scale to platform for growth in fire protection, security systems and water treatment services and looks forward to delivering a strong performance in  first full year of trading as a Group.  FYMar17E revs of £32.8m. EPS 7.1p. PE 23.6x


RedT Energy (RED.L) 8.12p £38m

The energy storage technology company, is working with Newcastle University in a Knowledge Transfer Partnership to research and develop the first ever hybrid energy storage system. The project has received £149,062 funding from Innovate UK partners; Engineering & Physical Sciences Research Council and the Scottish Funding Council.  The 3 year project aims to combine the redT flow energy storage machine with short duration power intensive storage solutions like lithium batteries.


Tern (TERN.L) 9.6p £7.6m

The company specialising in the cloud and Internet of Things sectors announced that its subsidiary, Device Authority, a specialist in policy & device driven security for IoT & a Gartner Cool Vendor, has formed a strategic partnership with DigiCert, a provider of  identity & authentication solutions, providing enhanced device provisioning & credential management for the IoT. The partnership helps expand & enable the range of IoT devices that can be secured with encryption, authentication & credential management.


Greatland Gold (GGP.L) 0.25p £4m

The precious and base metals exploration and development business announced that the Programme of Work application for the Ernest Giles gold project has been approved and field operations have now commenced.  The project covers a significant portion of a large greenstone belt that has been subject to little historical exploration. The large greenstone belts in Western Australia host multiple million ounce gold deposits and the intention is to determine whether similar deposits may be hosted within this remote and largely unexplored greenstone belt.


ImmuPharma (IMM.L) 34.5p £42m

The specialist drug discovery and development company, has updated on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease. 30 further patients to be enrolled at a new site in Mauritius where Lupus prevalence is high. Lupus Alert’, the country’s pre-eminent Lupus foundation has been following the progress of Lupuzor™ since the commencement of its pivotal Phase III trial.


Galantas Gold (GAL.L) 8.75p £12.06m

The gold developer in Northern Ireland has identified amongst its recent drilling results the presence of a gold vein stringer in the western part of the Kearney vein system. Core H159 (reported 24th August 2016) intersected 1 metre of mineralisation grading 5.7 g/t gold and 6.2 g/t silver. The vein stringer was not previously worked within the open pit because it lay close to the edge of the permitted open pit mining envelope.  This may allow earlier mining of ore than previously anticipated.


Scancell Holdings (SCLP.L) 18.25p £47.7m

The developer of novel immunotherapies for the treatment of cancer, announced that it will be presenting at the 23rd Annual NewsMakers in the Biotech Industry Conference. The conference is being held on 9 September 2016 at the Millennium Broadway Hotel & Conference Center in New York City, USA.


Immedia Group (IME.L) 26p £3.78m

The supplier of digital audio content solutions for leading brands and global businesses, announces has acquired the business and certain assets comprising AVC Media for £200k from AVC’s administrators. AVC Media’s last audited accounts for the year ended 31 March 2015, showed revenue of £5.9m, profit before tax of £0.09m and net assets of £0.08m. Immedia sees synergy and cost cutting opportunities.


Provexis (PXS.L) 0.49p £8.27m

The business that develops and licenses the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces its audited preliminary results for the year ended 31 March 2016.  Revenue from profit sharing Alliance for the year £92k, a 140% year on year increase. Total loss of £410k. Enhanced financial terms with DSM. Clinical trial on blood pressure to complete in Q4


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX. If you would like to unsubscribe, please email with “unsubscribe me”.